Abstract 420PD
Background
Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.
Methods
NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4 GBq every 8 weeks (x4 administrations) versus Octreotide LAR 60 mg every 4 weeks. The primary endpoint was PFS (RECIST 1.1). Secondary objectives included ORR, OS, toxicity, and quality of life (QoL) based upon EORTC QLQ-C30 and QLQ-G.I.NET21 questionnaires. Subgroup analysis of PFS was performed to assess impact of potential prognostic factors.
Results
The centrally confirmed disease progressions or deaths were 23 in the Lutathera arm and 68 in the Octreotide LAR 60 mg arm. The median PFS was not reached for Lutathera and was 8.4 months with control, p
Conclusions
The phase III NETTER-1 trial provides evidence for a clinically meaningful and statistically significant increase in PFS, and suggests an OS benefit in patients with advanced midgut NETs treated with Lutathera. Subgroup analysis demonstrates consistent benefit across prognostic factors. The Lutathera safety and QoL profile was found to be favorable.
Clinical trial identification
NCT01578239
Legal entity responsible for the study
Advanced Accelerator Applications
Funding
Advanced Accelerator Applications
Disclosure
J. Strosberg: Ipsen, Novartis, Genentech, Bayer.
E. Wolin: Novartis, Advanced Accelerator Applications.
B. Chasen, A. Hendifar, D. Kwekkeboom, D. Bushnell, M. Lopera Sierra: Advanced Accelerator Applications.
M. Kulke: Novartis Lexicon Ipsen.
M. Caplin: Novartis Pharma, Ipsen Pharma, Lexicon for advisory boards.
K. Oberg: Ipsen Novartis.
P. Ruszniewski: Ipsen Novartis Advanced Accelerator Applications.
E. Krenning: Mallinckrodt SKF Advanced Accelerator Applications.
All other authors have declared no conflicts of interest.
Resources from the same session
Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union
Presenter: Aurore Bergamasco
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Presenter: Martin Gutierrez
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
Presenter: Pierre Vanden Borre
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pancreatic neuroendocrine tumour (pNET) profiles in the NETwork! programme: clinic–enabled genomics for genomic-enabled clinical decisions
Presenter: Ben Lawrence
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Presentation
Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Presenter: Angela Lamarca
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
Presenter: Sara Pusceddu
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Invited discussant abstracts 427PD and 428PD
Presenter: Xavier Matias-Guiu
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Invited discussant abstracts 420PD, 421PD, 422PD and 423PD
Presenter: Rocio Garcia-Carbonero
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Invited discussant abstracts 416O and 417O
Presenter: James Yao
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Presenter: Matthew Kulke
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract